ceo headed to europe, page-175

Can do little more than echo ds.

I don't see any reason for pessimism, in biotech terms ADO is flying along, POC1 developments in Europe seem enormously positive, we're getting closer and closer to indispensable for their test platform (if we're not there already) nothing is certain in life but it seems more likely then ever that ADO will announce something big in relation to POC1 near-term and eventually be an integral part of the platform.

BBI are undoubtedly distracted by their float, but once it's done our opportunity there only grows larger, and again the longer we work with them and the longer the list of impressive achievements we chalk up, the harder it gets for them to walk away without a deal.

All the time we're gaining profile, and hopefully gaining traction with our in-house products and/or previous deals.

I've realised my posting has got a bit out of hand, and I'll be off travelling with work for a while, but I'll still be holding. I suspect the timing of the 'big' announcement when it comes will wrong-foot us all.